Hitachi Aloka Medical announces release of Ultrasound Bone Densitometry System at ECR 2015

Mr Minoru Yoshizumi, President of Hitachi Aloka Medical Ltd., Tokyo, Japan, is pleased to announce the release of EggQus, an extraordinary compact, portable Ultrasound Bone Densitometry System at the European Radiology Congress (ECR). Delegates will have the opportunity to see and test EggQus at the Hitachi Medical Systems booth 323, Expo C.

A new approach has been used in the development of the bone densitometry system, EggQus. It has been created using the design concept of an "eggshell", a shape born in nature. Simply beautiful, strong, lightweight, easy to handle. All of these features guarantee maximum portability.

Outstanding portability

EggQus is light, compact and versatile compared to conventional ultrasound bone densitometry systems. The large integrated handle facilitates in-hospital rounds and house visits.

Rechargeable battery operation

The system is powered by rechargeable batteries enhancing its portability. Continuous and convenient use can be sustained using the AC adapter accessory.

Easy operability

The motor-controlled transducer unit moves automatically, minimizing manipulation by the operator.

Measurement in approximately three seconds

The short measurement time is convenient for elderly examinees and for screening that requires rapid handling.

EggQus is available for delivery from March 2015 (Shipment time may vary depending on regulation and registration of the country).

Source:

Hitachi Medical Systems Europe Holding AG

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Experimental drug RK-33 shows promise in treating breast cancer bone metastasis